Antibiotic market into normal development
The latest data show that in 2014, the amount of antibacterial drugs for systemic use in public hospitals in key cities in China was 14.277 billion billion yuan, with a year-on-year growth rate of 9.85 percent. The most critical point is to optimize the medication structure, improve the level of medication, curb bacterial resistance, and ensure the safety of patients.
According to the report entitled "Antimicrobial Drugs: Global Market Forecast 2012-2022" released by the Visiongain Institute of Business Information in the United Kingdom, the compound annual growth rate of the global antimicrobial drug market is only 2.2 per cent from 2010 to 2022. Data show that the global antibacterial drug market in 2016 is about $43.8 billion. Among them, cephalosporins are still important antibiotic drugs for human use, and the sales of cephalosporins in the seven major pharmaceutical markets in the world will reach 11.671 billion US dollars. The analysis shows that due to the weak global antibiotic research and development pipeline in recent years and the rational and standardized use of some countries, overall, the growth of the global anti-infective drug market will enter a slow pace.
In 2012, the former Ministry of Health of China promulgated the "Administrative Measures for the Clinical Application of Antimicrobial Drugs"; in 2013, the National Health and Family Planning Commission issued the "2013 Special Rectification Activity Plan for the Clinical Application of Antimicrobial Drugs" to further establish and improve the management of clinical application of antimicrobial drugs. The long-term working mechanism, scientific and standardized use of antibacterial drugs, have promoted the normalized development of my country's antibacterial drug market.
market rigid demand
At present, the clinical use of antimicrobial agents in China mainly include β-lactams, macrolides and aminoglycosides. Among them, β-lactams are the most widely used and the highest clinical usage. Statistics show that β-lactam drugs account for more than 80% of antibiotics, including penicillin and its derivatives, cephalosporins, monoamide rings, carbapenems and penems enzyme inhibitors.
Known as the history of the "most stringent anti-bacterial order", the hospital systemic anti-bacterial drug market has been effectively constrained. Statistics show that 2012 was the most significant year for the decline in the domestic antibiotic market. In 2012, the amount of antibacterial drugs for systemic use in public hospitals in key cities in China was 13.139 billion yuan, down 17.09 percent from the previous year. In 2013, it still maintained a negative growth of 1.08 percent. However, with the rigid demand of the market and the widespread use of new products, the old drugs with greater side effects are gradually eliminated, and the antibiotic market will enter a healthy development of new normalization.
The latest data show that in 2014, the amount of antibacterial drugs for systemic use in public hospitals in key cities in China was 14.277 billion billion yuan, with a year-on-year growth rate of 9.85 percent. The most critical point is to optimize the drug structure, improve the level of drug use, curb bacterial drug resistance, and ensure the safety of patients. Various varieties of performance characteristics
According to the WHO classification, systemic anti-infective drugs can be divided into 14 subclasses. Among them, systemic antibacterial drugs are usually divided into 8 subclasses, namely cephalosporins, penicillins, macrolides and lincoms, aminoglycosides, quinolones, carbapenems, nitroimidazoles and other anti-infective drugs.
The data shows that in 2014, among the systemic antibacterial medicinal drugs used in public hospitals in key cities in China, the varieties with faster growth rate were compound cephalosporin preparations, carbon penicillins and compound semi-synthetic penicillins. These three categories of drugs increased by 23.78, 19.54 and 15.73 percent year-on-year. These drugs with higher growth rate are mostly injection varieties, hospital drugs and necessary drugs for surgery.
The categories that maintained low growth rates were semi-synthetic penicillins, macrolides, and lincor and cephalosporins, at -4.07, 2.37 and 3.7 per cent, respectively. The analysis shows that most of the categories with low growth rate belong to oral preparations, common drugs at the grass-roots level and retail drugs in pharmacies, indicating that the "measures for the Management of Clinical Application of Antimicrobial drugs" and the "2013 Special rectification activity Plan for Clinical Application of Antimicrobial drugs" have produced obvious results.
Characteristics of Drug Use in Hospitals of Domestic Cities
In the market letter of systemic antibacterial drugs in hospitals in key cities in China, Beijing, Shanghai, Guangzhou, Wuhan and Hangzhou are still in the top five. The growth rates of the above cities in 2014 are also different. Among them, the growth rate of Beijing in 2014 is 3.94, that of Shanghai is 7.48, that of Guangzhou is 7.22, that of Wuhan is 14.51, and that of Hangzhou is 8.93. From the data analysis, the use of antibacterial drugs for systemic use in Beijing is still growing at a low speed.